$4.25 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest



Vaccitech plc, formerly Vaccitech Ltd, is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer. The Company uses its platform to develop product candidates that target immune responses against pathogens and tumor cells. The Company has a pipeline of both clinical and preclinical stage therapeutic and prophylactic programs. Its therapeutic programs include VTP-300 for the treatment of chronic hepatitis B infection (CHB), VTP-200 for the treatment of human papilloma virus infection (HPV), VTP-850 for the treatment of prostate cancer and VTP-600 for the treatment of non-small cell lung cancer (NSCLC). Its prophylactic programs include VTP-400 for the prevention of herpes zoster (shingles), and VTP-500 for the prevention of the Middle East respiratory syndrome (MERS).

Stock Analysis

last close $4.6
1-mo return -19.7%
3-mo return -49.7%
avg daily vol. 28.86T
52-week high 17.99
52-week low 2.97
market cap. $150M
forward pe -
annual div. -
roe -31.2%
ltg forecast -
dividend yield -
annual rev. $11M
inst own. 8.6%

Subscribe now for daily local and international financial news